3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
12
Neoplasms
4
Recurrence
3
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinal Cord Neoplasms
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Glioma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Diseases
1
Interventions
Nivolumab
22
cabozantinib
13
Specimen Handling
12
Ipilimumab
11
Magnetic Resonance Spectroscopy
9
pembrolizumab
8
belzutifan
8
CTLA-4 Antigen
6
Axitinib
6
Biopsy
5
lenvatinib
4
Sunitinib
4
atezolizumab
3
Immunoglobulin G
3
Disulfides
3
zimberelimab
2
tivozanib
2
relatlimab
2
pazopanib
2
palbociclib
2
aldesleukin
2
X-Rays
2
Watchful Waiting
2
Radiosurgery
2
Bevacizumab
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
sodium-iodide symporter
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Renal Cell
×
abemaciclib
×
30 days
×
Clear all
No trials found.